We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
arlo
whitehouse
Arlo.Whitehouse@uhb.nhs.uk
Dr
Victoria
Wykes
v.wykes@bham.ac.uk
Dr
Victoria
Wykes
v.wykes@bham.ac.uk
Malignant neoplasms of eye, brain and other parts of central nervous system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
In 2016 there were 5250 deaths from brain tumours in the UK i.e. 14 deaths per day. Malignant central nervous system tumours hold the poorest prognosis, and are responsible for the highest estimated number of years of potential life lost (mean 20 years) amongst all cancers. Over the last few decades brain tumour survival trends have remained mainly static in comparison to other cancers.
We aim to capture the clinical imaging and biological data from sufficient patients to represent the phenotypic diversity seen in real world clinical practice of brain tumours and establish advanced brain tumour tissue modes in the laboratory. In this study, surplus brain tissue removed at surgery that is not required for clinical diagnosis will be used to establish brain tumour models. Other samples such as blood will be taken from selected patients to characterise circulating cell populations and markers of disease termed biomarkers. All adult patients (> 18 years) with a brain tumour presenting through our neuro-oncology multi-disciplinary meeting requiring a neurosurgical operation are eligible.
With improved understanding, we aim to identify novel biomarkers to allow earlier detection and diagnosis of brain tumours, and to better determine prognosis. Brain tissue models can act as a platform to help inform and test more “stratified” personal medical treatments. In this “bench to bedside” model, drugs can initially be tested in the laboratory before being used to direct patient’s clinical treatment. This research will provide greater understanding of the molecular evolution of brain cancers, and provide opportunities to allow earlier diagnosis, prognosis and subsequent intervention with the aim of improving survival coupled with a better quality of life.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
Case and Controls -Participants under the age of 18 years -Participants who are unable to give informed consent or are unwilling to participate -Participants with known high-risk infections (e.g. HIV/AIDS-positive, hepatitis B/C, tuberculosis and Creutzfeldt-Jacob disease).
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
arlo
whitehouse
Arlo.Whitehouse@uhb.nhs.uk
Dr
Victoria
Wykes
v.wykes@bham.ac.uk
Dr
Victoria
Wykes
v.wykes@bham.ac.uk
The study is sponsored by University of Birmingham and funded by Royal College of Surgeons of England .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 47533
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
